Abstract
Purpose:To report the outcomes of half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (CSC).Methods:A chart review of patients with chronic CSC who had received half-dose verteporfin PDT (3 mg/m2) was performed. The main outcome measures were resolution of subretinal fluid and best corrected visual acuity (BCVA).Results:Fifty-three eyes of 51 patients with mean age of 45.01 ± 8.9 years were studied. Three, 6 and 12 months after half-dose PDT, subretinal fluid was completely resolved in 51 eyes (96.2%). In 2 eyes (one patient), subretinal fluid decreased at 3 months but one year later, an increase in subretinal fluid was detected on optical coherence tomography (OCT) which completely resolved following additional PDT. Another patient with recurrence of subretinal fluid rejected further treatment. Mean baseline central subfield thickness was 385 ± 113.0 μm which was decreased to 235 ± 39.7, 247 ± 49.7, and 244 ± 49.52 μm after 3, 6 and 12 months, respectively (all P-values < 0.001). Mean BCVA was 0.33 ± 0.27 LogMAR before PDT and 0.11 ± 0.18, 0.11 ± 0.17, 0.17 ± 0.26 and 0.10 ± 0.23 LogMAR, 3, 6 and 12 months and at final visit (up to 60 months) after PDT, respectively (all P-values < 0.001). Improvement ≥2 lines in BCVA occurred in 20 eyes (37.7%). Statistically significant correlations were found between improvement in BCVA and baseline BCVA, baseline central subfield thickness and central subfield thickness after resorption of subretinal fluid (P < 0.001, P= 0.04 and P= 0.01, respectively). No complications attributed to PDT were observed.Conclusion:Half-dose PDT is effective for treatment of patients with chronic CSC.
Highlights
The aim of the present study is to report the outcomes of half‐dose photodynamic therapy (PDT) in a large series of patients with chronic Central serous chorioretinopathy (CSC)
Subretinal fluid resolved in 51 eyes (96.2%), 12 months after half‐dose PDT
In 2 eyes, subretinal fluid decreased at the 3‐month visit; it did not resolve completely and an increase in subretinal fluid was detected on optical coherence tomography (OCT) examination one year after PDT
Summary
Central serous chorioretinopathy (CSC) is characterizedReceived: 28-03-2015Accepted: 18-07-2015Access this article onlineQuick Response Code: Website: www.jovr.orgDOI: 10.4103/2008-322X.180706 by serous neurosensory retinal detachment and/or retinal pigment epithelial detachment (PED) at the posterior pole.[1] Typically, acute CSC is a self‐limited process which spontaneously resolves within 1‐4 months.[1] Accordingly, the current recommendation for management of acute CSC is observation and modification of risk factors.[2,3] Treatment is reserved for patients with fluid persisting more than 3 months, orThis is an open access article distributed under the terms of the Creative Commons Attribution‐NonCommercial‐ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non‐commercially, as long as the author is credited and the new creations are licensed under the identical terms.How to cite this article: Naseripour M, Ghasemi Falavarjani K, Sedaghat A, Karimi Moghaddam A, Nasserisina S, Alemzadeh SA. Half-dose photodynamic therapy for chronic central serous chorioretinopathy. J Ophthalmic Vis Res 2016;11:66-9.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
